TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma

NAActive, not recruitingINTERVENTIONAL

Enrollment

188

Participants

Timeline

Start Date

September 11, 2020

Primary Completion Date

August 31, 2024

Study Completion Date

January 31, 2026

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Camrelizumab

Camrelizumab: 200mg, iv, Q3W

DEVICE

TACE

TACE if necessary

DRUG

Apatinib

Apatinib: 250m, po, QD

Trial Locations (1)

Zhongda Hospital, Nanjing

All Listed Sponsors

lead

Zhongda Hospital

OTHER